tradingkey.logo
tradingkey.logo
Buscar

COSCIENS Biopharma Inc

CSCI
Añadir a la lista de seguimiento
2.720USD
0.0000.00%
Cierre 07/02, 13:00ETCotizaciones retrasadas 15 min
8.64MCap. mercado
PérdidaP/E TTM

Más Datos de COSCIENS Biopharma Inc Compañía

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.

Información de COSCIENS Biopharma Inc

Símbolo de cotizaciónCSCI
Nombre de la empresaCOSCIENS Biopharma Inc
Fecha de salida a bolsaDec 19, 1995
Director ejecutivoMs. Anna Biehn
Número de empleados- -
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 19
DirecciónC/O Norton Rose Fulbright Canada Llp
CiudadTORONTO
Bolsa de valoresThe Toronto Stock Exchange
PaísCanada
Código postalM5K 1E7
Teléfono18439003201
Sitio Webhttps://www.cosciensbio.com/
Símbolo de cotizaciónCSCI
Fecha de salida a bolsaDec 19, 1995
Director ejecutivoMs. Anna Biehn

Ejecutivos de COSCIENS Biopharma Inc

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Ulrich Kosciessa
Dr. Ulrich Kosciessa
Director
Director
1.85K
--
Mr. Robert A. Seager
Mr. Robert A. Seager
Director
Director
--
--
Ms. Nicola Ammer
Ms. Nicola Ammer
Senior Vice President - Clinical Development, Chief Medical Officer
Senior Vice President - Clinical Development, Chief Medical Officer
--
--
Dr. Matthias Gerlach
Dr. Matthias Gerlach
Senior Vice President - Manufacturing and Supply Chain, Managing Director - AEZS Germany
Senior Vice President - Manufacturing and Supply Chain, Managing Director - AEZS Germany
--
--
Mr. Giuliano La Fratta
Mr. Giuliano La Fratta
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
--
--
Mr. Michel Regnier
Mr. Michel Regnier
Senior Vice President, Chief Technology Officer
Senior Vice President, Chief Technology Officer
--
--
Mr. Ronald W. (Ronnie) Miller
Mr. Ronald W. (Ronnie) Miller
Director
Director
--
--
Mr. Peter H. Puccetti
Mr. Peter H. Puccetti
Chairman of the Board, Interim Chief Executive Officer
Chairman of the Board, Interim Chief Executive Officer
--
--
Mr. David Spear
Mr. David Spear
Director
Director
--
--
Mr. Anthony J. Giovinazzo
Mr. Anthony J. Giovinazzo
Director
Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Ulrich Kosciessa
Dr. Ulrich Kosciessa
Director
Director
1.85K
--
Mr. Robert A. Seager
Mr. Robert A. Seager
Director
Director
--
--
Ms. Nicola Ammer
Ms. Nicola Ammer
Senior Vice President - Clinical Development, Chief Medical Officer
Senior Vice President - Clinical Development, Chief Medical Officer
--
--
Dr. Matthias Gerlach
Dr. Matthias Gerlach
Senior Vice President - Manufacturing and Supply Chain, Managing Director - AEZS Germany
Senior Vice President - Manufacturing and Supply Chain, Managing Director - AEZS Germany
--
--
Mr. Giuliano La Fratta
Mr. Giuliano La Fratta
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
--
--
Mr. Michel Regnier
Mr. Michel Regnier
Senior Vice President, Chief Technology Officer
Senior Vice President, Chief Technology Officer
--
--

Preguntas frecuentes

¿Quiénes son los cinco principales accionistas de COSCIENS Biopharma Inc?

Los cinco principales accionistas de COSCIENS Biopharma Inc son: Dr. Ulrich Kosciessa

¿Cuántas instituciones poseen acciones de COSCIENS Biopharma Inc (CSCI)?

A fecha de 2026Q1, 31 instituciones poseen acciones de COSCIENS Biopharma Inc, con un valor de mercado combinado de aproximadamente 257.26K, lo que representa el 8.08% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -38426.00.